医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taro Announces Joining of CEO

2017年09月02日 AM05:05
このエントリーをはてなブックマークに追加


 

HAWTHORNE, N.Y.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today that Mr. Uday Baldota has joined the Company as its Chief Executive Officer (“CEO”) effective August 28, 2017. Since December 2016, Mr. Baldota has served as a member of Taro’s Board of Directors (“Taro Board”).

Mr. Baldota replaces Mr. Abhay Gandhi, who served in the role of Interim Chief Executive Officer since January 1, 2017. Mr. Gandhi will continue in his role as Vice Chairman of the Taro Board and as the CEO of the Sun Pharma North America operations.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170901005726/en/

CONTACT

Taro Pharmaceutical Industries Ltd.
Mariano Balaguer, 914-345-9001
VP,
Chief Financial Officer
Mariano.Balaguer@taro.com
or
William
J. Coote,
914-345-9001
AVP, Business Finance, Treasurer and
Investor Relations
William.Coote@taro.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作